Home LiteratureArticle Details
PMID: 1674549 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Blocking of human immunodeficiency virus infection depends on cell density and viral stock age.

Journal of virology ·Vol. 65 ·No. 6 ·1991-06-00 ·Pages 3293-300

Layne SP, Merges MJ, Spouge JL, Dembo M, Nara PL

Abstract

Quantitative infectivity assays were used to study how the blocking activity of soluble CD4 (sCD4) is affected by sCD4 concentration, target cell density, and viral stock age. During incubation with 20 nM sCD4, human immunodeficiency virus type 1 (HIV-1) stocks underwent irreversible inactivation. In contrast, inactivation with 2 nM sCD4 was almost entirely reversible. At lower sCD4 concentrations (less than or equal to 2 nM) and target cell densities of 6.25 x 10(4) ml-1, sCD4 blocking activity for HIV-1 gave a gp120-sCD4 association constant (Kassoc) of 1.7 x 10(9) M-1, which agrees with chemical measurements. At the higher density of 1.6 x 10(7) cells ml-1, however, the blocking activity was 20-fold less. During incubation of HIV-1 stock optimized for infectivity by rapid harvest, sCD4 blocking activity increased 20-fold during a 3-h window. These results show that competitive blocking activity depends strongly on target cell density and virion age. Thus, unappreciated variations in HIV stocks and assay conditions may hinder comparisons of blockers from laboratory to laboratory, and the age of HIV challenge stocks may influence studies of drug and vaccine efficacy. The results also suggest that blocking of viral particles in lymphoid compartments will require very high competitive blocker concentrations, which may explain the refractory outcomes from sCD4-based drug trials in humans.

MeSH Terms
Acquired Immunodeficiency Syndrome/immunology Binding, Competitive CD4 Antigens/immunology CD4-Positive T-Lymphocytes/immunology,microbiology Cells, Cultured HIV Antibodies/immunology HIV Envelope Protein gp120/immunology HIV-1/growth & development Humans Time Factors Viral Vaccines Virion/immunology
Chemicals
CD4 Antigens HIV Antibodies HIV Envelope Protein gp120 Viral Vaccines
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Layne S P
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, New Mexico 87545.
Merges M J
Spouge J L
Dembo M
Nara P L
References (59)
59 references, click to expand
  1. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
    Science. 1990 Dec 14;250(4987):1590-3 PMID: 1703322
  2. Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?
    Lancet. 1985 Nov 2;2(8462):1016-7 PMID: 2865493
  3. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains.
    Nature. 1990 Nov 29;348(6300):411-8 PMID: 1701030
  4. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
    J Virol. 1991 Feb;65(2):852-60 PMID: 1898972
  5. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    J Virol. 1991 Mar;65(3):1133-40 PMID: 1995942
  6. Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
    Science. 1990 Nov 23;250(4984):1139-42 PMID: 2251501
  7. Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.
    AIDS Res Hum Retroviruses. 1990 Oct;6(10):1209-12 PMID: 2252640
  8. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
    Cell. 1986 Nov 7;47(3):333-48 PMID: 3094962
  9. Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
    Nature. 1988 Jan 7;331(6151):84-6 PMID: 2829024
  10. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.
    Nature. 1988 Jan 7;331(6151):78-81 PMID: 2829023
  11. HIV infection is blocked in vitro by recombinant soluble CD4.
    Nature. 1988 Jan 7;331(6151):76-8 PMID: 2829022
  12. Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding.
    Nature. 1988 Sep 22;335(6188):363-6 PMID: 2843773
  13. Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity.
    Science. 1988 Aug 5;241(4866):712-6 PMID: 2969619
  14. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.
    J Immunol. 1985 Nov;135(5):3151-62 PMID: 2995487
  15. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.
    J Clin Invest. 1985 Aug;76(2):875-7 PMID: 2993366
  16. Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection.
    AIDS. 1989;3 Suppl 1:S119-23 PMID: 2482053
  17. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.
    J Virol. 1989 Sep;63(9):3579-85 PMID: 2474670
  18. Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.
    Proc Natl Acad Sci U S A. 1988 Dec;85(23):9273-7 PMID: 2461565
  19. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.
    AIDS Res Hum Retroviruses. 1988 Jun;4(3):187-97 PMID: 2456088
  20. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6 PMID: 2450351
  21. Neutralizing monoclonal antibodies to the AIDS virus.
    AIDS. 1988 Feb;2(1):25-9 PMID: 2451922
  22. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    J Virol. 1988 Jun;62(6):2107-14 PMID: 2452899
  23. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.
    Cell. 1988 Apr 8;53(1):55-67 PMID: 2450679
  24. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.
    J Virol. 1987 Jun;61(6):2024-8 PMID: 2437327
  25. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.
    Science. 1986 Dec 12;234(4782):1392-5 PMID: 2431482
  26. Analytic results for quantifying HIV infectivity.
    Bull Math Biol. 1989;51(6):715-30 PMID: 2555003
  27. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.
    J Virol. 1989 Oct;63(10):4370-5 PMID: 2550671
  28. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
    Nature. 1989 May 4;339(6219):68-70 PMID: 2541344
  29. Designing CD4 immunoadhesins for AIDS therapy.
    Nature. 1989 Feb 9;337(6207):525-31 PMID: 2536900
  30. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.
    Nature. 1989 Jan 26;337(6205):368-70 PMID: 2536142
  31. Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques.
    Nature. 1989 Jan 19;337(6204):267-70 PMID: 2536140
  32. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.
    Science. 1988 Feb 26;239(4843):1021-3 PMID: 2830667
  33. Viral persistence.
    Cell. 1989 Feb 24;56(4):517-20 PMID: 2645053
  34. CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle.
    Proc Natl Acad Sci U S A. 1989 Sep;86(18):7139-43 PMID: 2789382
  35. Inhibition of HIV-1 replication and syncytium formation by synthetic CD4 peptides.
    Arch Virol. 1989;105(1-2):129-35 PMID: 2785788
  36. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  37. Quantifying the infectivity of human immunodeficiency virus.
    Proc Natl Acad Sci U S A. 1989 Jun;86(12):4644-8 PMID: 2734313
  38. Quantitative infectivity assay for HIV-1 and-2.
    Nature. 1988 Mar 31;332(6163):469-70 PMID: 3281026
  39. A soluble form of CD4 (T4) protein inhibits AIDS virus infection.
    Nature. 1988 Jan 7;331(6151):82-4 PMID: 3257544
  40. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4.
    Nature. 1988 Jul 14;334(6178):159-62 PMID: 3260352
  41. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8 PMID: 6083454
  42. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 PMID: 6096719
  43. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.
    Science. 1987 Dec 18;238(4834):1704-7 PMID: 3500514
  44. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.
    AIDS Res Hum Retroviruses. 1987 Fall;3(3):283-302 PMID: 3481271
  45. Induction of anti-HIV neutralizing antibodies by synthetic peptides.
    EMBO J. 1986 Nov;5(11):3065-71 PMID: 3466790
  46. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.
    Virology. 1987 Jan;156(1):171-6 PMID: 3643678
  47. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.
    Science. 1987 Sep 11;237(4820):1351-5 PMID: 3629244
  48. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
    J Virol. 1990 Aug;64(8):3779-91 PMID: 2370681
  49. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Nature. 1990 Jun 14;345(6276):622-5 PMID: 2190095
  50. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.
    AIDS. 1990 Apr;4(4):297-305 PMID: 2190604
  51. Differences in the interaction of HIV-1 and HIV-2 with CD4.
    J Acquir Immune Defic Syndr. 1990;3(7):649-57 PMID: 1693676
  52. Biological properties of a CD4 immunoadhesin.
    Nature. 1990 Apr 12;344(6267):667-70 PMID: 1970124
  53. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Proc Natl Acad Sci U S A. 1990 Sep;87(17):6574-8 PMID: 2395859
  54. HIV requires multiple gp120 molecules for CD4-mediated infection.
    Nature. 1990 Jul 19;346(6281):277-9 PMID: 2374593
  55. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
    Ann Intern Med. 1990 Feb 15;112(4):254-61 PMID: 2297204
  56. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Ann Intern Med. 1990 Feb 15;112(4):247-53 PMID: 2297203
  57. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82 PMID: 2454471
  58. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  59. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    J Virol. 1991 Jan;65(1):489-93 PMID: 1702163
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1991-06-00
Pages
3293-300
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC240987
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com